Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
Source link
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
Source link
